SCHEMBL6997925

SCHEMBL6997925

CC(=O)OCC1OC(OC(C)=O)C(OC(C)=O)[C@@H](C)[C@H]1C

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 0.54
THRB P10828 1/20 0.54
HSD17B10 Q99714 1/20 0.54
CA2 P00918 10/20 0.49
LMNA P02545 2/20 0.48
TSHR P16473 1/20 0.46
NR3C1 P04150 1/20 0.46
FYN P06241 1/20 0.46
ADRA2A P08913 1/20 0.46
ADORA3 P0DMS8 1/20 0.46
ADRA2B P18089 1/20 0.46
DRD4 P21917 1/20 0.46
DRD3 P35462 1/20 0.46
CA12 O43570 9/20 0.45
CA1 P00915 8/20 0.45
CA9 Q16790 7/20 0.45
CA4 P22748 2/20 0.42
CA5A P35218 2/20 0.42
CA7 P43166 2/20 0.42
CA5B Q9Y2D0 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12136363 1.00 CYP2D6 (0.54) CYP2D6THRBHSD17B10CA2LMNA
SCHEMBL10310559 1.00 CYP2D6 (0.54) CYP2D6THRBHSD17B10CA2LMNA
SCHEMBL26535396 1.00 CYP2D6 (0.54) CYP2D6THRBHSD17B10CA2LMNA
SCHEMBL25484579 1.00 CYP2D6 (0.54) CYP2D6THRBHSD17B10CA2LMNA
SCHEMBL10028968 1.00 CYP2D6 (0.54) CYP2D6THRBHSD17B10CA2LMNA
SCHEMBL16939977 1.00 CYP2D6 (0.54) CYP2D6THRBHSD17B10CA2LMNA
SCHEMBL16546896 1.00 CYP2D6 (0.54) CYP2D6THRBHSD17B10CA2LMNA
SCHEMBL15480324 1.00 CYP2D6 (0.54) CYP2D6THRBHSD17B10CA2LMNA
SCHEMBL26824159 1.00 CYP2D6 (0.54) CYP2D6THRBHSD17B10CA2LMNA
SCHEMBL15504376 1.00 CYP2D6 (0.54) CYP2D6THRBHSD17B10CA2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240209029-A1 ADIPONECTIN GLYCOPEPTIDES AND COMPOSITIONS AND METHODS OF USE THEREOF THE UNIVERSITY OF HONG KONG (CN) 2024-06-27 US disclosed
US-8211859-B2 α-galactoceramide analogs, their methods of manufacture, intermediate compounds useful in these methods, and pharmaceutical compositions containing them CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2012-07-03 US disclosed
US-8183355-B2 Method for the synthesis of oligonucleotide derivatives CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2012-05-22 US disclosed
US-20110245478-A1 Method for the Synthesis of Oligonucleotide Derivatives CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) 2011-10-06 US disclosed
US-20110028411-A1 ALPHA-GALACTOCERAMIDE ANALOGS, THEIR METHODS OF MANUFACTURE, INTERMEDIATE COMPOUNDS USEFUL IN THESE METHODS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM CENTRE NATIONAL DE LA RECHERCHE SCIENTIFQUE (FR) 2011-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028411-A1 ALPHA-GALACTOCERAMIDE ANALOGS, THEIR METHODS OF MANUFACTURE, INTERMEDIATE COMPOUNDS USEFUL IN THESE METHODS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM GALE, GALNT14, GALC CYP2D6 746/4885THRB 2757/4885HSD17B10 1170/4885
US-20240209029-A1 ADIPONECTIN GLYCOPEPTIDES AND COMPOSITIONS AND METHODS OF USE THEREOF ADIPOR1, ADIPOR2, PTMS CYP2D6 3216/4885THRB 621/4885HSD17B10 1189/4885
US-20110245478-A1 Method for the Synthesis of Oligonucleotide Derivatives MSN, RNGTT, DCLRE1B CYP2D6 3308/4885THRB 2185/4885HSD17B10 3897/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.